Study on the virological and immunological effects of sintilimab combined with targeted and antiviral methods in the treatment of hepatitis B virus associated hepatocellular cancer
Shen Jiao
Yang Daokun
Wang Yanping
Liu Jia
Wei Shuai
Chen Baoxin
Abstract：Objective To observe the virological and immunological effects of programmed cell death protein 1 inhibitors sintilimab combined with targeted and antiviral methods in the treatment of hepatitis B virus(HBV)associated hepatocellular cancer.Methods Totally 70 patients with HBV associated hepatocellular cancer admitted to the First Affiliated Hospital of Xinxiang Medical University from March 2021 to April 2022 were selected.They were completely randomized into control group and observation group,with 35 cases in each group.The control group was treated with tenofovir alafenamide and targeted therapy,while the observation group was treated with sintilimab on the basis of the control group.The changes in virological and immunological indicators of patients before treatment and in the first,third,and sixth cycles of treatment were observed and compared.Results In the third and sixth cycles of treatment,the quantitative negative rate of HBV DNA in the observation group was higher than that in the control group[71.4％(25/35)vs 37.1％(13/35),94.3％(33/35)vs 54.3％(19/35)],and the differences were statistically significant(both P＜0.01).There was no statistically significant difference in HBV surface antigen quantification between the observation group and the control group before treatment and in the first,third,and sixth cycles of treatment(all P＞0.05),but the magnitude of decline of HBV surface antigen quantification level in the observation group was greater than that in the control group in the first,third,and sixth cycles of treatment.In the first,third,and sixth cycles of treatment,the number of CD4+T lymphocytes,CD8+T lymphocytes,and natural killer cells in the control group gradually decreased,while those in the observation group gradually increased,and the numbers in the observation group were more than those in the control group(all P＜0.05).Conclusions The combination of sintilimab and targeted and antiviral methods has a good therapeutic effect on HBV associated hepatocellular cancer,and is superior to simple antiviral combined targeted therapy in reducing virus replication ability and improve patients'immune function.
Keywords：Hepatocellular cancerProgrammed cell death protein 1 inhibitorsHepatitis B virusImmune function
Publication Date：2024-02-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 240-243 )